Business Wire

YOKOGAWA-ELECTRIC

Share
Yokogawa Provides Remote Operation/Monitoring System and Video Monitoring Solution for Japan’s Largest Wind Farm

Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary Yokogawa Solution Service Corporation has completed the design, supply, and commissioning of a remote operation and monitoring system based on the OpreX™ Collaborative Information Server for the offshore wind turbines and onshore facilities at the Ishikari Bay New Port Offshore Wind Farm. The company has also contracted to provide maintenance services at this wind farm, which is operated by JERA Co., Inc. and the Green Power Investment Corporation and owned through Green Power Ishikari GK, a special-purpose corporation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213110562/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ishikari Bay New Port Offshore Wind Farm (Source: Green Power Investment Corporation)

The Ishikari Bay New Port Offshore Wind Farm is the first wind farm in Japan to use large-scale 8,000kW wind turbines, and as of the start of commercial operations on January 1, 2024, it is the largest commercial wind farm in Japan. The remote operation and monitoring system supplied by Yokogawa includes a video system for the monitoring of all the offshore and onshore wind power generating facilities at this wind farm. On an ongoing basis, the company will also provide maintenance services for these systems.

At the core of this remote operation and monitoring system is Yokogawa’s Collaborative Information Server, a solution that offers centralized management of data from the offshore wind turbines, the transformer substation’s large-scale storage batteries, and cameras installed on the wind turbines and storage batteries, and in the turbine maintenance yard. This video monitoring system utilizes the Edge Gateway AG 10 (for indoor) solution provided by Yokogawa subsidiary amnimo Inc.

Wind is a renewable energy source, and the amount of electricity produced varies depending on weather conditions. Taking into account information on power demand provided by the transmission system operator, this remote operation and monitoring system provides the data required to control the amount of power that will be stored by the storage battery system.

In addition to the systems delivered for this project, Yokogawa Solution Service has also received orders from Green Power Investment Corporation for systems that will aggregate information in real-time from wind farms all around Japan, and link this with cloud-based analysis tools. And together with Green Power Investment, Yokogawa Solution Service has commenced proof-of-concept tests in which the DTSX3000 optical fiber temperature sensor, a product in the OpreX Field Instruments lineup, is utilized to detect signs of damage to the submarine cables at the Ishikari Bay New Port Offshore Wind Farm.

Yokogawa is firmly focused on developing the system of systems (SoS) concept, whereby systems work together as a whole while maintaining operational and management independence to achieve, in an emergent way, goals that cannot be achieved independently. While there are many types of equipment and system configurations at wind farms, Yokogawa possesses the operational technology (OT) know-how needed to interpret data from sensors and other devices and thereby identify how the equipment and systems should be linked to achieve optimization at the individual and collective levels. By leveraging this know-how to provide solutions that cover everything from operation to overall system maintenance, Yokogawa will contribute to the realization of a decarbonized society.

About Yokogawa

Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 129 companies spanning 60 countries.
For more information, visit www.yokogawa.com

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, or their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213110562/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release

SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye